9905600-4
IPOS copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 401/04, C07F 7/08, A61K 31/44, 31/695, C07D 401/14, 451/02, 403/04, A61K 31/445

A1

(11) International Publication Number: **WO 99/01449**

(43) International Publication Date: 14 January 1999 (14.01.99)

(21) International Application Number: PCT/EP98/03930

(22) International Filing Date: 26 June 1998 (26.06.98)

(30) Priority Data:
9713726.9 30 June 1997 (30.06.97) GB

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1235 Vienna (AT).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: RÉVÉSZ, Lászlo [CH/CH]; Ob dem Fichtenrain 7, CH–4106 Therwil (CH).

(74) Agent: BECKER, Konrad; Novartis AG, Patent– und Markenabteilung, Lichtstrasse 35, CH–4002 Basel (CH).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

REPLACED SHEETS SG

☑ Description	: paged 1	to paged 25
☑ Claim(s)	: paged 26	to paged 31
☐ Drawing(s)	: paged	to paged .....
☐ Abstract	: paged	to paged .....

(54) Title: 2–SUBSTITUTED 4,5–DIARYL IMIDAZOLES



(I)

(57) Abstract

Novel 2–substituted 4,5–diaryl imidazoles in which: i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl–containing substituent, or ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono– or bicyclic N–heterocyclyl in which the N containing ring has six ring members, are provided, in particular compounds of Formula (I) wherein R_1, R_2, R_3 and R_4 are as defined, in free or pharmaceutically–acceptable acid additon salt or physiologically–cleavable ester form, which have p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. The compounds are used as pharmaceuticals for treating TNFα and IL–1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.